Whilst radiolabelled substrate probes for hormone receptors have shown promise for imaging response to endocrine therapy, the progression to hormone independence and emergence of endocrine resistance with loss of ER expression is a widely recognized phenomenon in breast cancer, and has been reported to occur in up to 35% of cases [33]. Here, ESR1 is linked to breast carcinoma.